Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
08:00am, Thursday, 28'th Aug 2025
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
01:01pm, Monday, 25'th Aug 2025
Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
10:56am, Friday, 08'th Aug 2025
Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
09:11am, Tuesday, 05'th Aug 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
07:00am, Tuesday, 05'th Aug 2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
07:00am, Thursday, 22'nd May 2025
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
09:25am, Wednesday, 14'th May 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
07:00am, Wednesday, 14'th May 2025
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show s
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
07:00am, Monday, 05'th May 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
07:00am, Thursday, 01'st May 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
07:00am, Tuesday, 15'th Apr 2025
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target populat
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
07:05pm, Thursday, 06'th Mar 2025
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago.
